Scinovex
reviewTop 10% cited

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

Psychopharmacology · 2003 · Vol. 169(3-4) · pp. 215–233
John H. KrystalDeepak Cyril D’SouzaDaniel H. MathalonEdward PerryAyşenil BelgerRalph E. Hoffman
Neuroscience and Neuropharmacology ResearchTryptophan and brain disordersTreatment of Major DepressionNMDA receptorGlutamatergicDisinhibitionSchizophrenia (object-oriented programming)NeurosciencePsychologyGlutamate receptorPsychosisAntagonistPhencyclidine

MeSH terms

AnimalsCerebral CortexCognitionHumansKetamineModels, NeurologicalNeural PathwaysSchizophreniaAntipsychotic AgentsReceptors, N-Methyl-D-AspartateExcitatory Amino Acid AntagonistsGlutamic Acid
Citations
531
FWCI
5.78
field-weighted impact
References
308
Percentile
98%
vs. same field & year
Citations per year
Cited by
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development · Scinovex